
InterWest Partners
Description
InterWest Partners, a historically significant venture capital firm based in Menlo Park, California, is no longer making new investments. Established in 1979, the firm announced its wind-down phase, focusing solely on managing its existing portfolio to exit. This means InterWest Partners is not an active investor for new companies seeking capital, and prospective entrepreneurs should be aware that the firm is not deploying new funds.
Throughout its operational history, InterWest Partners was a prominent investor in both information technology and healthcare sectors. The firm managed substantial capital, having raised approximately $2.8 billion across 10 funds over its tenure. Its last fund, InterWest X, closed in 2007 with $650 million, underscoring its significant presence in the venture capital landscape for decades. Historically, InterWest invested across various stages, from seed to late-stage rounds, demonstrating a flexible approach to company growth.
When active, InterWest Partners was known for its long-term commitment to portfolio companies, often investing an average of $7 million to $15 million over the span of their involvement with each company. Their investment strategy aimed to support companies through multiple growth phases, contributing to numerous successful exits. While their legacy includes backing innovative companies and achieving significant returns for their limited partners, their current focus is exclusively on the divestment of remaining assets, marking the end of their new investment activities.
Investor Profile
InterWest Partners has backed more than 393 startups, with 0 new investments in the last 12 months alone. The firm has led 79 rounds, about 20% of its total and boasts 125 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series A rounds (top funding stages).
- Majority of deals are located in United States, Australia, China.
- Strong thematic focus on Health Care, Biotechnology, Software.
Stage Focus
- Series B (21%)
- Series C (18%)
- Series A (17%)
- Series D (15%)
- Series Unknown (13%)
- Series E (6%)
- Seed (4%)
- Series F (3%)
- Series G (1%)
- Private Equity (1%)
Country Focus
- United States (96%)
- Australia (2%)
- China (2%)
- Canada (1%)
Industry Focus
- Health Care
- Biotechnology
- Software
- Medical
- Medical Device
- Manufacturing
- Therapeutics
- Enterprise Software
- Saas
- Analytics
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.